All relevant data are available in the manuscript, its Supporting Information files, and via the NCBI Gene Expression Omnibus (GEO) under accession number GSE69020.

Introduction {#sec001}
============

Crohn's disease (CD) is a form of inflammatory bowel disease (IBD) that is characterized by skip lesions of transmural inflammation, and can occur at multiple sites in the digestive tract. Inflammation can be found anywhere in the gastrointestinal tract from the mouth to the anus, but in most (60--80%) CD patients, the distal small intestine is frequently involved \[[@pone.0130902.ref001], [@pone.0130902.ref002]\]. Factors implicated in the pathogenesis of IBD include host genetic predisposition, and continual activation of the mucosal immune system by luminal bacteria and their products \[[@pone.0130902.ref003], [@pone.0130902.ref004]\]. From 16S ribosomal RNA gene sequence data, several laboratories have demonstrated imbalances in the gut microbial composition of CD patients, particularly those with ileal involvement when compared to unaffected individuals \[[@pone.0130902.ref005]--[@pone.0130902.ref016]\]. A consistent feature is a reduction in the relative frequency of *Faecalibacterium prausnitzii* \[[@pone.0130902.ref008]\] and an increase in Proteobacteria, particularly *Escherichia coli* \[[@pone.0130902.ref005]\]. A greater relative abundance of *E*. *coli* has been associated with CD, and particularly in active disease compared to patients in remission \[[@pone.0130902.ref017]\]. Mucosa-associated *E*. *coli* in particular are more abundant in CD \[[@pone.0130902.ref018]\] and in several small studies were isolated from inflamed tissue that include areas with ulcers and granulomas \[[@pone.0130902.ref019], [@pone.0130902.ref020]\]. In addition *E*. *coli* from the neoterminal ileum in post-surgical CD patients are linked to early recurrence of the disease \[[@pone.0130902.ref002]\].

Adherent invasive *E*. *coli* (AIEC) are considered to be pathobionts \[[@pone.0130902.ref021]--[@pone.0130902.ref023]\] and are isolated from the intestinal mucosa in humans with a higher prevalence in CD patients than in healthy subjects \[[@pone.0130902.ref002], [@pone.0130902.ref024], [@pone.0130902.ref025]\]. The AIEC phenotype requires adherence and invasion of intestinal epithelial cells and survival and replication within macrophages \[[@pone.0130902.ref026], [@pone.0130902.ref027]\]. Only a few commensal *E*. *coli* have been tested for this phenotype \[[@pone.0130902.ref028]\]. Using these methods, AIEC strains are detected in 22--52% of ileal CD patients and in 6--18% of non-IBD subjects \[[@pone.0130902.ref002], [@pone.0130902.ref018], [@pone.0130902.ref029]--[@pone.0130902.ref031]\]. However, these studies differ with respect to the number of biopsies analyzed, the anatomical location of the biopsies, and disease activity.

The design of a culture independent assay is hindered by the fact that although AIEC usually belong to the B2 or D groups, they are phylogenetically heterogeneous \[[@pone.0130902.ref018], [@pone.0130902.ref032]\]. Jensen et al \[[@pone.0130902.ref033]\] reported a quantitative real-time PCR (RT-qPCR) to determine the proportion of *E*. *coli* LF82 in DNA from human intestinal biopsies using spiked samples, but has not reported the results of this assay using clinical samples. Furthermore the genomic target of this assay, the pMT1-like plasmid, is not conserved among AIEC. Dogan et al,\[[@pone.0130902.ref034]\] reported that genes encoding processes responsible for propanediol utilization (*pdu* operon) and iron acquisition (yersiniabactin, *chu* operon) are overrepresented in human and dog AIEC genomes and might represent AIEC virulence factors.

To gain insight into biological pathways that contribute to AIEC pathogenicity we conducted a comparative transcriptomic analysis of the reference AIEC strain LF82 and the non-invasive commensal strain HS, grown in pure cultures. Furthermore, the genomic sequences of 11 non-invasive *E*. *coli* strains, including MG1655 \[[@pone.0130902.ref035]\] and HS \[[@pone.0130902.ref036]\], and a panel of 13 AIEC strains \[[@pone.0130902.ref034], [@pone.0130902.ref037]--[@pone.0130902.ref041]\] were compared to identify coding regions that could potentially serve as AIEC probes. Five of these gene targets and the previously described gene *pduC*, were tested by reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) following extraction of RNA from fecal and ileal biopsy samples from 53 patients with and without IBD.

Materials and Methods {#sec002}
=====================

Homology searches in AIEC and non-invasive *E*. *coli* genomic sequences {#sec003}
------------------------------------------------------------------------

The characteristics of seven previously published human AIEC (strains LF82, UM146, NRG857c, HM605, 541_1, 541_15, 576_1) and three human NIEC (strains T75, HS and MG-1655), are summarized in [Table 1](#pone.0130902.t001){ref-type="table"}. Reference genomes were retrieved from NCBI \[[@pone.0130902.ref028], [@pone.0130902.ref034]--[@pone.0130902.ref041]\]. The characteristics of the six AIEC (strains MS-107-1, MS-115-1, MS-119-1, MS124-1, MS145-7, MS57-2), and 8 NIEC (strains MS185-1, MS187-1, MS196-1, MS198-1, MS45-1, MS60-1, MS78-1, MS84-1) are also listed in [Table 1](#pone.0130902.t001){ref-type="table"}. These MS strains were isolated from de-identified surgical resection specimens collected at Mount Sinai School of Medicine \[[@pone.0130902.ref006]\] from CD, UC and non-IBD patients and characterized with respect to AIEC phenotype. The genomes of these 14 *E*. *coli* strains are accessible through the Human Microbiome Project database \[[@pone.0130902.ref042]\]. Homologous CDS were compared for these 13 AIEC and 11 NIEC. A search was also conducted among diarrheagenic (DEC) and extraintestinal (ExPEC) pathogenic *E*. *coli* ([S1 Table](#pone.0130902.s005){ref-type="supplementary-material"}) using the alignment tool BLASTN (version 2.2.28+). Homologous genes were defined as those with ≥85% sequence identity over 90 to 110% of the length of the query as previously described \[[@pone.0130902.ref037]\].

10.1371/journal.pone.0130902.t001

###### Characteristics of 13 human AIEC and 10 non-invasive E. coli isolates.

The AIEC phenotype was assessed using gentamycin protection assays of epithelial invasiona and survival within macrophages. The IBD affectation status was described as CD, UC or non-IBD. The anatomic site or source was the ileum, colon or feces. The pathology if available was described as macroscopically unaffectred or diseased or was not documented (-). For feces, the pathology was not applicable (N.A.) The K12-MG1655 strain was cured from K12 and has been maintained as a laboratory strain. The orginal K12 strain was isolated from a patient suffering from diphtheria.
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  E. coli strain   AIEC phenotype   IBD affectation status   Anatomic site   Pathology    Reference
  ---------------- ---------------- ------------------------ --------------- ------------ ----------------------------
  LF82             AIEC             CD                       ileum           diseased     \[[@pone.0130902.ref037]\]
  NRG857c          AIEC             CD                       ileum           \-           \[[@pone.0130902.ref038]\]
  UM146            AIEC             CD                       ileum           \-           \[[@pone.0130902.ref040]\]
  HM605            AIEC             CD                       colon           \-           \[[@pone.0130902.ref039]\]
  541_1            AIEC             CD                       ileum                        \[[@pone.0130902.ref034]\]
  541_15           AIEC             CD                       ileum                        \[[@pone.0130902.ref034]\]
  576_1            AIEC             CD                       ileum                        \[[@pone.0130902.ref034]\]
  MS-107-1         AIEC             CD                       ileum                        
  MS-115-1         AIEC             UC                       colon           diseased     
  MS-119-7         AIEC             CD                       colon           \-           
  MS-124-1         AIEC             CD                       ileum           unaffected   
  MS-145-7         AIEC             CD                       colon           \-           
  MS-57-2          AIEC             Non-IBD                  ileum           unaffected   
  HS               Non-invasive     Non-IBD                  feces           N.A.         \[[@pone.0130902.ref036]\]
  K12-MG1655       Non-invasive     Non-IBD                  feces           N.A.         
  T75              Non-invasive     CD                       ileum           \-           \[[@pone.0130902.ref034]\]
  MS-185-1         Non-invasive     Non-IBD                  colon           unaffected   
  MS-187-1         Non-invasive     Non-IBD                  colon           unaffected   
  MS-196-1         Non-invasive     Non-IBD                  colon           unaffected   
  MS-198-1         Non-invasive     Non-IBD                  colon           unaffected   
  MS-45-1          Non-invasive     UC                       colon           diseased     
  MS-60-1          Non-invasive     Non-IBD                  colon           diseased     
  MS-78-1          Non-invasive     UC                       colon           diseased     
  MS-84-1          Non-invasive     CD                       ileum           unaffected   

Bacterial RNA isolation, sequencing and alignment to genomes {#sec004}
------------------------------------------------------------

The reference AIEC strain LF82, originally isolated by Dr. Darfeuille-Michaud, was provided as a gift by Dr. Phillip Sherman (University of Toronto) and its identity was confirmed by multi-locus sequence typing\[[@pone.0130902.ref043]\]. The non-invasive HS strain was purchased from American Type Culture Collection (ATCC 700891). Triplicate Luria broth cultures (37°C) of LF82 and HS were grown with continuous shaking for 2 hours (exponential phase) and 24 h without shaking (stationary phase). Total RNA was extracted from the cells using the RiboPure Bacteria kit (Life Technologies Corp. Carlsbad, CA), following the manufacturer's protocol. The average RNA Integrity Number (RIN) over all samples was 7. Two micrograms of RNA was depleted of ribosomal RNA using the RiboMinus Transcriptome Isolation Kit (Life Technologies Corp. Carlsbad, CA). These samples were then used as a template for strand-specific cDNA synthesis and subjected to single-end 150 bp Illumina sequencing. The RNA-Seq libraries were prepared and sequenced at the New York Genome Center (NYGC). Raw sequences were filtered to remove human sequence contamination, remove short reads (\< 50 bp), depleted of duplicate reads, and quality trimmed using Trimmomatic (v 0.32) \[[@pone.0130902.ref044]\]. rRNA sequences were identified and culled using SortMe RNA (v1.9) \[[@pone.0130902.ref045]\]. Raw sequence reads for LF82 and HS were mapped to NCBI reference genomes NC_011993 and NC_009800, respectively \[[@pone.0130902.ref037]\] using the Burroughs Wheeler aligner (BWA) \[[@pone.0130902.ref046]\]. Counts for each annotated genomic loci were determined by HTseq-count (version 0.6.1) \[[@pone.0130902.ref047]\]. The data discussed in this publication have been deposited in NCBI\'s Gene Expression Omnibus and are accessible through GEO Series accession number GSE69020.

Differentially Expressed Genes (DEGs) in LF82 compared to HS {#sec005}
------------------------------------------------------------

Two DEG algorithms were employed, edgeR \[[@pone.0130902.ref048]\] and DESeq \[[@pone.0130902.ref049]\]. The raw counts produced by HTseq-count provided the input variables for the DESeq and edgeR packages. DEGs were defined as ≥ 2 fold change and FDR \< 0.05 and LF82 and HS transcripts were compared at 2h or 24h, independently. DEGs resulting from edgeR were the input variables for knowledge based biological functions using the Gene Ontology (GO) plugin BiNGO \[[@pone.0130902.ref050]\] and the custom ontology and annotation files found on the Gene Ontology website \[[@pone.0130902.ref051], [@pone.0130902.ref052]\]. DEGs resulting from DESeq were the input variables for knowledge based pathways/modules defined either by the Kyoto Encyclopedia of Genes and Genomes (KEGG, <http://www.genome.jp/kegg/>) \[[@pone.0130902.ref053]\] or a set of modules obtained through clustering a network of high quality functional interactions predicted for *E*. *coli* \[[@pone.0130902.ref054]\]. The up-regulated and down-regulated output from DESeq for each time point were entered to identify the perturbed pathways regardless of the overall polarity.

Ethics Statement {#sec006}
----------------

This study was approved by the Institutional Review Board (IRB) at Stony Brook University Hospital. Pediatric (age ≥ 7 years) and adult patients are recruited in a consecutive fashion by the Stony Brook Digestive Diseases Research Tissue Procurement Facility and provide verbal and written consent for chart abstraction, blood, stool, tissue biopsies and/or surgical waste collection with analysis for research purposes and for their information to be stored in the hospital database. For children between 7--17 years old participating in this study, both oral and written parent/legal guardian permission and a separate oral and written assent from the child was obtained. The IRB at Stony Brook University Hospital approved this consent procedure.

Enrollment of patients and collection of samples {#sec007}
------------------------------------------------

After receiving IRB approval, participants previously scheduled to undergo colonoscopy or intestinal resection, were identified and consented. Pediatric (ages ≥7 years) and adult patients were recruited in a consecutive fashion by the Stony Brook Digestive Diseases Research Tissue Procurement Facility. The period of enrollment was between March 2011 and June 2014. Patients with a confirmed diagnosis of IBD were phenotyped based on endoscopic and radiographic studies as previously described \[[@pone.0130902.ref055]\]. Tissue specimens were collected and immediately placed into RNAlater (Life Technologies, Carlsbad, CA).

DNA isolation from bacteria {#sec008}
---------------------------

Nine bacterial strains were processed for DNA isolation: LF82, MG1655, HS, and 6 MS AIEC strains. Following overnight culture, a single colony of each bacterial strain was placed in 5 ml of tryptic soy broth and incubated overnight at 37°C with shaking. Total bacterial DNA was extracted using the QIAamp DNA Mini Kit and according to the manufacturer's protocol and stored at -20°C until batch analysis.

PCR and electrophoresis {#sec009}
-----------------------

The forward and reverse primers for the *Cas* genes (strains LF82_088, LF82_091, LF82_092 and LF82_093) were designed using the NCBI primer designing tool Primer-BLAST \[[@pone.0130902.ref056]\]. The *E*. *coli* 16S rRNA forward and reverse primers were previously validated \[[@pone.0130902.ref057]\]. The predicted PCR products were 340 bp for *E*. *coli* 16S rRNA, 107 bp for LF82_088, 109 bp for LF82_091, 97 bp for LF82_092, and 125 bp for LF82_093. Amplification was performed in a 15 μL reaction volume and consisting of 1.5 μL 10X PCR buffer (Qiagen), 3 μL Q solution, nuclease free water, 0.5 μM forward and reverse primers, 0.1 uL Qiagen Taq DNA polymerase, and 1μL template. PCR was performed using an Eppendorf Mastercycler EPGradient S. The following thermal cycling conditions were used: 5 min at 94°C and 36 cycles of amplification consisting of 30 seconds at 95°C, 30 seconds at 56°C, and 1 min at 72°C, with 5 min at 72°C for the final extension. PCR product bands were analyzed after electrophoresis in a 1% agarose gel in 1X TBE containing ethidium bromide and digital imaging using The ChemiDoc MP system (Biorad, Hercules, CA).

RNA isolation from stool and bacteria {#sec010}
-------------------------------------

Total bacterial RNA was extracted from each stool sample using a fecal RNA isolation kit (Zymo Research Corporation, Irvine, CA) according to the manufacturer's protocol. RNA from strains LF82, MG1655, and HS was extracted using the same kit after culture for 2 and 24 hours. RNA was archived at -80^0^ C until batch analysis.

RNA isolation from ileal biopsies {#sec011}
---------------------------------

Fresh frozen ileal biopsies were homogenized individually in 2 ml of Trizol solution (Life Technologies) with the PowerGen125 homogenizer (Fisher Scientific) and 1 ml aliquots placed into 1.5 mL microcentrifuge tubes. RNA was subsequently extracted using phenol/chloroform extraction methods as previously described\[[@pone.0130902.ref058]\]. The RNA was reconstituted in 50ul of RNA Storing Solution (Life Technologies) and stored at -80^0^ C until batch analysis.

Reverse transcription quantitative polymerase chain reaction (RT-qPCR) of *E*. *coli* transcripts {#sec012}
-------------------------------------------------------------------------------------------------

For cDNA production, 500 nanograms of RNA was added to a 20 μL reaction using the SuperScript VILO cDNA Synthesis Kit (Life Technologies, Carlsbad, CA). Quantitative PCR was conducted in triplicate on 1:2 dilutions of cDNA from fecal samples and 1:2, 1:4 and 1:8 dilutions of cDNA from pure *E*. *coli* cultures and using 1 μL volumes. Amplification was performed in a 20 μL reaction volume and consisting of 10 μl of 2x SYBR Green Master Mix, 1 μl each of 10uM forward and reverse primers, 1 μL of cDNA, and 7 μL of nuclease free water. The thermal cycling conditions were: 10 min at 95°C and 40 cycles of amplification consisting of 30 seconds at 95°C and 60 seconds at 60°C using a Mastercycler EPGradient S (Eppendorf). Primers included Total bacteria and *E*. *coli* 16S rRNA forward and reverse primers as previously validated \[[@pone.0130902.ref057]\] and the *pduC* gene as previously described \[[@pone.0130902.ref034]\]. Primers were designed for 5 candidate genes LF82_088, LF82_091, LF82_092, LF82_093, and LF82_095, using an online primer design tool\[[@pone.0130902.ref056]\]. The sequences of all primers are listed in [S2 Table](#pone.0130902.s006){ref-type="supplementary-material"}.

Statistical analysis {#sec013}
--------------------

All analyses were performed using the GraphPad Prism 5 software suite (GraphPad, San Diego, CA). For each RT-qPCR assay, the average cycle threshold (Ct) of 3 replicates per gene was determined. Positive assays had a mean threshold cycle values (Ct) ≤35. The Ct values in negative samples and water ranged from 39--40. Fisher's exact test was performed to compare positive and negative counts in IBD compared to non-IBD and CD compared to non-IBD, for fecal and ileal biopsy samples, respectively. The relative abundance of *E*. *coli* 16S rRNA transcripts was determined by defining the delta Ct (ΔCt). ΔCt was generated by subtracting the average Ct value for total bacteria away from the average Ct value of *E*. *coli* 16S rDNA. The nonparametric Mann-Whitney test was used to compare values for IBD compared to non-IBD and CD compared to non-IBD for fecal and ileal biopsy samples, respectively.

Results {#sec014}
=======

Identification of differentially expressed genes (DEG) in LF82 vs. HS {#sec015}
---------------------------------------------------------------------

We analyzed gene expression levels of strains LF82 and HS in separate samples prepared from exponential (2h) and stationary (24h) phase cultures grown at 37°C, in order to interrogate gene expression under different growth conditions. Expression levels were standardized by reads per kilobase of exon per million mapped sequence reads (RPKM) \[[@pone.0130902.ref059]\]. The edgeR and the DESeq algorithms yielded similar findings. Results generated using edgeR are shown in [S1 File](#pone.0130902.s003){ref-type="supplementary-material"}. For the 2h and 24h samples, 654 and 459 CDS, respectively, had increased expression (RPKM ≥2 fold, FDR \<0.05) in LF82 compared to HS (Table A in [S1 File](#pone.0130902.s003){ref-type="supplementary-material"}), with 224 of the CDS exhibiting increased expression in LF82 at both time points. At 2 h, 6 genes shared by LF82 and HS were expressed only in LF82. Similarly at 24 h, 17 genes had detectable transcripts in LF82 and not in HS (Table A in [S1 File](#pone.0130902.s003){ref-type="supplementary-material"}). Six genes were detected only in LF82 at both time points. Some of these genes are involved in bacteriophage infections and others have no known function ([Table 2](#pone.0130902.t002){ref-type="table"}). A total of 712 and 492 genes had decreased expression at 2h and 24h respectively, in LF82 compared to HS (Table B in [S1 File](#pone.0130902.s003){ref-type="supplementary-material"}), with 241 genes exhibiting decreased expression in LF82 (RPKM ≤ 0.05, FDR \<0.05) at both time points.

10.1371/journal.pone.0130902.t002

###### These 6 CDS are homologous in LF82 and HS but transcripts are detected only in LF82 at both 2h and 24 h.

The LF82 NCBI Locus Tags and the bacterial gene names (if available) are shown. The mean normalized RPKM at 2h and 24 h is shown.
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  LF82 NCBI Locus Tag   Gene     Function                                 Bacteria with identical protein                                                     RPK 2h   RPK 24h
  --------------------- -------- ---------------------------------------- ----------------------------------------------------------------------------------- -------- ---------
  LF82_119                       phage NinH protein                       *Escherichia*                                                                       92.9     19.6
  LF82_121                       Holin--pore forming protein              *E*. *coli*, *Salmonella enterica* subsp. Enterica, *S*. *flexneri* bacteriophage   62.8     6.8
  LF82_126                       hypothetical protein                     *E*. *coli*, *Shigella*                                                             111.6    13.2
  LF82_134                       Phage head assembly protein              *E*. *coli*, *Salmonella*, *S*. *flexneri*                                          47.1     6.6
  LF82_135                       DNA transfer protein                     *E*. *coli*, *Salmonella*, *Shigella*, *Cronobacter* bacteriophage                  109.7    7.0
  LF82_2871             *ydiE*   inorganic ion transport and metabolism   *E*. *coli*                                                                         44.2     47.4

Functional profiling of genes was accomplished using the Gene Ontology (GO) plugin BiNGO \[[@pone.0130902.ref050]\] and the custom ontology and annotation files on the Gene Ontology website (<http://www.geneontology.org>). This analysis revealed that multiple functional categories have overlapping datasets as shown in Tables A-D in [S2 File](#pone.0130902.s004){ref-type="supplementary-material"}. Examples include "siderophore metabolic process like enterobactin", which are up-regulated at both time points, and"glycogen metabolic process" and "oxidation-reduction process", which are down regulated at both time points ([Table 3](#pone.0130902.t003){ref-type="table"}). Analysis using alternative pathways/modules gene sets \[[@pone.0130902.ref053], [@pone.0130902.ref054]\] facilitated visualization of patterns of gene expression against a very complex background. For example, the functional category chemotaxis is up-regulated (FDR = 0.008) in LF82 at 2h, but bacterial-type flagellum-dependent cell motility is down regulated (FDR = 1.4 x 10^−6^) at 24h. However as shown in [Fig 1](#pone.0130902.g001){ref-type="fig"}, the polarity of the DEGs are preserved at both time points. These network-based results draw attention to modules that do not overlap with the GO categories (e.g. modules 24 and 79 in [Fig 1](#pone.0130902.g001){ref-type="fig"}).

![Functional modules differentially expressed in strain LF82 compared to non-invasive strain HS at 2h and 24h time points.\
As mentioned above, the differences can not be related to the duration of culture vs. the agitation. Functional modules were obtained from a high quality set of protein-protein interaction previously defined for *E*. *coli* \[[@pone.0130902.ref036]\]. Node size indicates fold change (log2) of differential expression (DE) based on the DESeq algorithm \[[@pone.0130902.ref033]\]. Node color indicates direction of regulation. Flagella and chemotaxis module: (a) most chemotaxis genes are up-regulated in LF82 relative to HS at 2h (DE \> 3), while at 24h (b), half of the flagella genes are down-regulated in LF82 (DE \> 2). (c) Most nitrate reductase genes are down-regulated in LF82 at 2h (DE \> 2). (d) At 2 hours, iron-sulphur cluster assembly genes in LF82 are down-regulated (DE \> = 2.7), and enterobactin synthesis genes (involved in iron transport) are up-regulated (DE \> = 2.3).](pone.0130902.g001){#pone.0130902.g001}

10.1371/journal.pone.0130902.t003

###### Selected common up-regulated and down-regulated biological pathways in LF82 at 2h and 24h time points.

For more comprehensive lists of up-regulated and down-regulated pathways at 2h and 24h please see **[S2A and S2B Table](#pone.0130902.s006){ref-type="supplementary-material"}**. The false discovery rate (FDR) is indicated for both the 2h and 24h cultures.
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  GO--ID   Pathway Genes at 24h time point                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   2h FDR      24h FDR
  -------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------- ---------
           ***Up-regulated pathways***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  41       Transition metal transpor*t*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      0.0017      0.0045
           *COPA\|FIU\|FEPA\|FEOB\|FES\|FEPE\|RCNA\|YCDO\|ZNUA\|YCDB\|MODC\|CUSC\|YDAN\|CUSB*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  9247     Siderophore metabolic process                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     0.00035     0.0020
           *ENTE\|ENTF\|ENTC\|YBDZ\|ENTA\|FES\|ENTB*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
           ***Down-regulated pathways***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  5977     Glycogen metabolic process                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        0.0031      0.043
           *GLGS\|GLGC\|GLGA\|GLGX\|GLGP*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  55114    Oxidation-reduction process                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       0.0000022   0.00018
           *TDCE\|HYCF\|MAEB\|YEIA\|TDCD\|HYCD\|HYCE\|FUMA\|FUMC\|FUMB\|YGHZ\|YEIT\|ASPA\|NRFC\|METF\|TPX\|YPHC\|YDJL\|NARH\|PDXB\|PFLA\|YDBK\|GLTA\|YOAE\|ARGC\|GLGC\|HYBC\|MELA\|HYBA\|HYBB\|HYBO\|FADB\|FADA\|FADE\|GLGP\|NUOK\|GLGS\|SUCB\|SUCA\|SUCD\|SUCC\|YAJO\|FDOI\|TRXA\|GLGX\|FDOG\|TRXC\|FDOH\|YGCO\|UBID\|UBIF\|YHBW\|YGCN\|XDHA\|NAPH\|GND\|FRE\|NAPF\|XDHB\|XDHD\|DADA\|NAPA\|YBDH\|YJJN\|RSPB\|YDHU\|ILVC\|NDH\|YDHV\|GLGA\|TYRA\|YGGP\|STHA\|FADJ\|ALLD\|YHJA\|LIPA\|HDHA\|IDND\|FUCO\|LPD\|SDHA\|YGFK\|YBAE\|DSBG\|DUSA\|SDHC\|PUTA\|YGFM\|SDHD\|YFEX\|YDEP\|UCPA\|YDEM*               

Selection of candidate AIEC signature transcripts {#sec016}
-------------------------------------------------

To identify candidate AIEC signature transcripts, we took a subtractive approach to identify coding DNA sequences that were present in the genome of the reference AIEC strain LF82 but not homologous to sequences in 11 non-invasive *E*. *coli* strains. In addition to the HS and MG1655 strains, we included 9 strains from patients with and without IBD and phenotyped with respect to their inability to invade epithelial cells and survive within macrophages. Although five of the non-invasive strains were isolated from non-IBD patients, four others were isolated from IBD patients (2 UC, 2 CD) ([Table 1](#pone.0130902.t001){ref-type="table"}). Of the 4508 predicted CDS in the LF82 genome \[[@pone.0130902.ref037]\], 3446 could be uniquely mapped to corresponding CDS with ≥ 85% sequence identity in the control HS genome. Although 747 LF82 CDS lacked homology to the HS genome \[[@pone.0130902.ref036]\] further subtraction was accomplished by including 10 additional NIEC. In the final analysis, 166 CDS in LF82 were absent from all 11 NIEC genomes.

We compared the 166 CDS across six published AIEC genomes (UM146, NRG857c, HM605, 541--1, 541--15, 576--1) and six MS AIEC strains (MS-107-1, MS-115-1, MS-119-1, MS124-1, MS145-7, MS57-2). None of the 166 CDS were homologous to all 13 human AIEC genomes (see [S1 Table](#pone.0130902.s005){ref-type="supplementary-material"}). The CDS LF82_95, which encodes an excisionase, was the most prevalent with homology in 9 of 13 AIEC genomes (see [Table 4](#pone.0130902.t004){ref-type="table"} and [S1 Table](#pone.0130902.s005){ref-type="supplementary-material"}). This CDS also shared homology with a number of pathogenic *E*. *coli*, particularly DEC (see [S1 Table](#pone.0130902.s005){ref-type="supplementary-material"}). The CDS LF82_332 corresponds to the *pduC* gene and was homologous with 6 of 13 AIEC. We also selected 4 CDS (LF82_089, LF82_091, LF82_091, LF82_092, and LF82_093) that mapped to a region previously described as "specific region 6" \[[@pone.0130902.ref037]\] and corresponded to 4 CRISPR-Cas genes. Three AIEC (LF82, NRG857c, and MS-57-2) shared homologous CDS with all 6 candidate AIEC transcripts. Three AIEC strains 541_1, 576_1, and MS--115--1), shared only the *pduC* gene and 3 additional AIEC strains (UM146, HM605, and MS-145-7) shared only the 4 Cas genes.

10.1371/journal.pone.0130902.t004

###### LF82 transcripts that share homology with at least 4 other AIEC genomes but none of the 11 NIEC genomes.

(See also **[S3 Table](#pone.0130902.s007){ref-type="supplementary-material"}**). Putative protein function is based on sequence homology as listed in NCBI GENE. The mean RPKM are show in the 2h and 24 h LF82 cultures. The number of AIEC strains (total of 13) with CDS sharing \>85% sequence homology is listed. The genes selected for exploratory RT-qPCR analysis of patient samples are in **bold.**
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  RefSeq ID      Putative protein                                                                   2h RPKM    24h RPKM   No. AIEC
  -------------- ---------------------------------------------------------------------------------- ---------- ---------- ----------
  **LF82_095**   **excisionase**                                                                    **10.3**   **8.4**    **9**
  **LF82_088**   **CRISPR/Cas system-associated protein Cas1**                                      **11.3**   **28.3**   **6**
  LF82_089       CRISPR/Cas system-associated protein Cas3/Cas2                                     22.2       39.9       6
  **LF82_092**   **CRISPR/Cas system-associated RAMP superfamily protein Csy3**                     **29.5**   **31.8**   **6**
  **LF82_093**   **CRISPR/Cas system-associated RAMP superfamily protein Cas6f**                    **12.0**   **9.7**    **6**
  LF82_328       cobalamin biosynthesis protein CbiG                                                16.7       13.0       6
  LF82_330       propanediol diffusion facilitator                                                  0.7        3.3        6
  LF82_331       propanediol utilization protein:polyhedral bodies                                  0.2        0.7        6
  **LF82_332**   **propanediol utilization protein: glycerol dehydratase large subunit (*pduC*)**   **0.5**    **2.4**    **6**
  LF82_333       propanediol utilization protein: diol dehydratase medium subunit                   1.1        4.0        6
  LF82_334       propanediol utilization protein: diol dehydratase small subunit                    0.6        1.3        6
  LF82_335       propanediol utilization protein: diol dehydratase reactivation                     0.6        2.8        6
  LF82_336       propanediol utilization protein: diol dehydratase reactivation                     1.4        3.3        6
  LF82_337       propanediol utilization protein: polyhedral bodies                                 9.1        13.6       6
  LF82_338       propanediol utilization protein: polyhedral bodies                                 1.0        2.3        6
  LF82_339       propanediol utilization protein                                                    0.5        3.5        6
  LF82_340       propanediol utilization protein                                                    1.4        5.5        6
  LF82_341       propanediol utilization protein: polyhedral bodies                                 1.1        2.9        6
  LF82_342       propanediol utilization protein: B12 related                                       1.5        2.9        6
  LF82_343       CoAdependent proprionaldehyde dehydrogenase                                        2.1        4.5        6
  LF82_344       propanediol utilization protein: propanol dehydrogenase                            0.6        0.9        6
  LF82_345       propanediol utilization protein                                                    1.0        2.9        6
  LF82_346       propanediol utilization protein: polyhedral bodies                                 2.1        4.1        6
  LF82_347       propanediol utilization protein: polyhedral bodies                                 2.2        3.5        6
  LF82_778       putative propanediol utilization protein                                           0.2        3.4        6
  LF82_013       hypothetical protein                                                               12.8       12.5       5
  LF82_090       hypothetical protein                                                               17.7       13.2       5
  LF82_199       iron compound ABC transporter                                                      0.2        0.9        5
  LF82_348       propanediol utilization protein                                                    3.8        6.1        5
  **LF82_091**   **CRISPR-associated protein (Cas_Csy2)**                                           **14.4**   **6.2**    **4**
  LF82_329       Pdu/cob regulatory protein                                                         7.3        10.8       4
  LF82_389       variable tail fibre protein                                                        0.7        3.2        4
  LF82_441       hypothetical protein                                                               9.1        21.9       4
  LF82_548       major fimbrial subunit                                                             11.3       21.3       4
  LF82_550       outer membrane usher protein lpfC precursor                                        33.1       51.7       4
  LF82_551       fimbrial chaperone protein                                                         0.2        0.9        4
  LF82_552       fimbrial-like protein                                                              3.6        3.5        4
  LF82_723       DHA kinase PgdK (EC 27129)                                                         15.6       16.7       4
  LF82_724       dihydroxyacetone kinase PdaK (EC271 29)                                            1.4        5.4        4
  LF82_725       glycerol dehydrogenase CgrD (EC1116)                                               8.8        5.3        4
  LF82_726       transporter CgxT                                                                   1.3        2.3        4
  LF82_727       dihydrolipoamide dehydrogenase CdlD                                                3.5        5.4        4
  LF82_728       carnitine transporter CniT                                                         3.0        7.9        4
  LF82_729       glycerate kinase GclK                                                              2.4        6.6        4
  LF82_730       3hydroxyisobutyrate dehydrogenase GhbD(EC 11131)                                   1.9        2.9        4
  LF82_731       regulatory protein GclR                                                            1.8        3.1        4
  LF82_732       glycoxylate carboligase GclA                                                       0.6        1.7        4
  LF82_733       regulatory protein IbgR                                                            4.7        6.0        4
  LF82_734       Invasion protein IbeA                                                              2.5        4.5        4
  LF82_735       transporter IbgT                                                                   1.3        3.0        4

To test the *in silico* results and validate the PCR primers we amplified DNA for each of the 4 candidate genes ([S1 Table](#pone.0130902.s005){ref-type="supplementary-material"}). Agarose gel electrophoresis of PCR reactions verified amplification products of the expected sizes (see [methods](#sec002){ref-type="sec"}) for candidate genes LF82_091, LF82_092, LF82_093 and LF82_088 in strains LF82, MS145-7, and MS57--2 ([S2 Table](#pone.0130902.s006){ref-type="supplementary-material"}). All other strains, including MG1655, HS and the 4 MS AIEC strains without homologous Cas genes, exhibited no PCR amplification with these primers. All samples produced the expected band at 340 base pairs for the *E*. *coli* 16S rRNA gene product ([S1](#pone.0130902.s001){ref-type="supplementary-material"} & [S2](#pone.0130902.s002){ref-type="supplementary-material"} Figs).

Screening Candidate Gene Transcripts in Human Clinical Specimens {#sec017}
----------------------------------------------------------------

RNA was isolated from fecal samples collected from 53 individuals at Stony Brook University. Within this collection, 43 (81.1%) stool samples were acquired from children ([Table 3](#pone.0130902.t003){ref-type="table"}). Twenty-two were IBD patients and 31 individuals were non-IBD controls. Non-IBD patients included subjects with functional GI disorders, Celiac disease, lactose intolerance and one patient with juvenile polyps. The number of male patients was significantly higher in both IBD cohorts compared to controls, p = 0.009 and 0.029 for CD and UC respectively. CD patients were significantly older (p = 0.024). The median ages for CD, UC/IC and controls were 20, 16 and 15 years, respectively. The IBD patients included 14 patients with CD, 6 patients with UC and 2 with indeterminate colitis (IC). Three of the CD patients were diagnosed at enrollment. Parallel ileal biopsies were available for 10 CD patients, 3 UC patients and 23 non-IBD controls. [Table 5](#pone.0130902.t005){ref-type="table"} displays the characteristics of all subjects. For IBD patients, age of diagnosis, disease location and disease behavior (CD) are as defined by the Montreal classification\[[@pone.0130902.ref060]\]. Also included are disease duration, body mass index (BMI), smoking, surgical management of IBD, and IBD medications.

10.1371/journal.pone.0130902.t005

###### Clinical characteristics of CD, UC/IC and non-IBD patients.

![](pone.0130902.t005){#pone.0130902.t005g}

                                                                          CD N = 14         UC/IC N = 8       Non-IBD N = 32
  ----------------------------------------------------------------------- ----------------- ----------------- ------------------
  Gender                                                                                                      
  Male                                                                    11 (85%)          7 (88%)           11 (35%)
  Age of Diagnosis, (Montreal A)                                                                              
  A1 (≤16 yr)                                                             71.4              87.5              
  A2 (17--40 yr)                                                          28.5              12.5              
  A3 (\>40 yr)                                                                                                
  Disease Location, CD (Montreal L)                                                                           
  L1 ileal                                                                21.4                                
  L2 colonic                                                              7.1                                 
  L3 ileocolonic                                                          71.4                                
  Disease Location, UC (Montreal E)                                                                           
  E1 proctitis                                                                              12.5              
  E2 left-sided                                                                                               
  E3 extensive                                                                              83.0              
  Disease Behavior, CD (Montreal B)                                                                           
  B1 nonstricturing, nonpenetrating                                       57.1                                
  B2 stricturing)                                                         21.4                                
  B3 penetrating---excludes perianal                                      21.4                                
  Median age at procedure (IQR)[^a^](#t005fn001){ref-type="table-fn"} y   20 (14.2--25.7)   16 (12.7--17.2)   15 (11--17)
  Median duration of disease (IQR) y                                      4.5 (1.4--6.8)    1.5 (0--10)       
  Race                                                                                                        
  Caucasian                                                               11 (85%)          6 (75%)           28 (88%)
  Current Smoker                                                          1                 0                 1
  Median BMI (IQR) kg/m2                                                  21.0 (17--24)     19.8(18.7--22)    20.1(17.5--24.5)
  Medications                                                                                                 
  Mesalamine[^b^](#t005fn002){ref-type="table-fn"}                        5 (36%)           1 (12%)           0
  Steroids                                                                2 (14%)           1 (12%)           
  Immunomodulators[^c^](#t005fn003){ref-type="table-fn"}                  4 (29%)           1 (12%)           
  Anti TNF alpha biologics[^d^](#t005fn004){ref-type="table-fn"}          7 (50%)           1 (12%)           

^a^IQR: Interquartile range

^b^Mesalamine: Balsalazide, Mesalamine, Olsalazine, Sulfasalazine

^c^Immunomodulators: Imuran, Methotrexate

^d^Biologics: Adalimumab, Certolizumab, Infliximab

To compare the relative abundance of *E*. *coli* between clinical specimens, we performed RT-qPCR with *E*. *coli*-specific 16S rRNA gene primers and normalized results to total bacterial 16S rRNA gene expression (Tables [6](#pone.0130902.t006){ref-type="table"} & [7](#pone.0130902.t007){ref-type="table"}). The median ΔCT values (Total-*E*. *coli* Ct) among CD, UC/IC and non-IBD fecal samples were -14.40, -7.14, and -13.56, respectively. There was no statistically significant difference in *E*. *coli* abundance compared to non-IBD controls. Among ileal biopsy specimens, the mean ΔCT values for CD, UC/IC and non-IBD samples were -9.94, -10.50, and -11.84, respectively. There was no statistically significant elevation in *E*. *coli* abundance in IBD specimens compared to controls.

10.1371/journal.pone.0130902.t006

###### Fecal RT-qPCR results for candidate AIEC transcripts.

The number of positive fecal stool samples are shown for each candidate AIEC transcript. Transcript is defined by LF82 locus tag and hypothetical function. Fisher's exact tests were used to compare the frequencies of positive results. "\*" represents P values of \<0.05. The median ΔCt~E.\ coli~ (range) is shown. The nonparametric Mann-Whitney test was used to compare values for IBD compared to non-IBD and CD compared to non-IBD for fecal and ileal biopsy samples, respectively.

![](pone.0130902.t006){#pone.0130902.t006g}

  Transcript                           CD                   UC/IC               Non-IBD              P value   P-value
  ---------------------- ------------- -------------------- ------------------- -------------------- --------- ---------
  LF82_095               excisionase   9                    4                   14                   0.41      0.34
  LF82_332               *pduC*        3                    3                   8                    1.00      1.00
  LF82_088               *cas1_I-F*    5                    1                   2                    0.05      0.02\*
  LF82_091               *cas_Csy2*    5                    1                   2                    0.05      0.02\*
  LF82_092               *csy3_I-F*    5                    1                   2                    0.05      0.02\*
  LF82_093               *cas6_I-F*    1                    0                   1                    1.00      0.52
  Median ΔCt~E.\ coli~   (IQR)         -14.4                -7.4                -13.6                0.48      0.81
                                       (-17.54 to -11.85)   (-12.81 to -4.80)   (-18.10 to -11.41)             

10.1371/journal.pone.0130902.t007

###### Ileal RT qPCR results for candidate AIEC transcripts.

The number of positive ileal biopsy samples are shown for each candidate AIEC transcript. Transcript is defined by LF82 locus tag and hypothetical function. Fisher's exact tests were used to compare the frequencies of positive results. "\*" represents P values of \<0.05. The median ΔCt~E.\ coli~ (interquartile range) is shown. The nonparametric Mann-Whitney test was used to compare values for IBD compared to non-IBD and CD compared to non-IBD for fecal and ileal biopsy samples, respectively.

![](pone.0130902.t007){#pone.0130902.t007g}

  Transcript                           CD                    UC/IC               Non-IBD             P value   P-value
  ---------------------- ------------- --------------------- ------------------- ------------------- --------- ---------
  LF82_095               excisionase   4                     0                   0                   0.74      .0095\*
  LF82_332               *pduC*        2                     0                   1                   0.55      0.27
  LF82_088               *cas1_I-F*    9                     2                   11                  0.09      0.16
  LF82_091               *cas_Csy2*    6                     0                   3                   0.12      0.04
  LF82_092               *csy3_I-F*    6                     0                   3                   0.12      0.04
  LF82_093               *cas6_I-F*    3                     0                   0                   0.05      0.03
  Median ΔCt~E.\ coli~   (IQR)         -9.9                  -10.5               -11.8               0.08      0.12
                                       (---11.92 to -7.35)   (-10.89 to -6.83)   (-16.56 to -9.60)             

The threshold of detection of transcripts corresponding to excisionase (LF82_095), *pduC* (LF82_332) and four Cas homologous genes (LF82_088, LF82_091, LF82_092, and LF82_093 was set at Ct ≤ 35. The negative Ct values ranged between 39 and 40. A higher proportion of CD fecal ([Table 6](#pone.0130902.t006){ref-type="table"}) and ileal ([Table 7](#pone.0130902.t007){ref-type="table"}) cDNA samples were positive for LF82_091 and LF82_092 transcripts than non-IBD fecal and ileal RNA samples (p \<0.05) A higher proportion of CD fecal samples were positive for LF82_088 in CD vs. non-IBD samples and a higher proportion of CD ileal samples were positive for LF82_093 AND LF82_095 in CD vs. non-IBD.

The median ΔCT values (Total-*E*. *coli* Ct) among CD, UC/IC and non-IBD fecal samples were -14.40, -7.14, and -13.56, respectively. There was no statistically significant difference in *E*. *coli* abundance when compared to non-IBD controls. Among ileal biopsy specimens, the mean ΔCT values for CD, UC/IC and non-IBD samples were -9.94, -10.50, and -11.84, respectively. There was no statistically significant elevation in *E*. *coli* abundance in IBD specimens compared to controls.

Discussion {#sec018}
==========

Although a higher proportion of CD patients harbor AIEC, such organisms can also be recovered from non-IBD patients. Conversely, NIEC strains are recovered from IBD patients ([Table 1](#pone.0130902.t001){ref-type="table"}). The pathogenic potential of AIEC may vary depending on host susceptibility. Host factors such as IBD risk alleles and Paneth cell function have been linked to alterations in ileal mucosa-associated microbial composition and the *Escherichia/Shigella* genus \[[@pone.0130902.ref012], [@pone.0130902.ref014], [@pone.0130902.ref057], [@pone.0130902.ref061], [@pone.0130902.ref062]\]. *In-vitro* analysis has not been performed for many human commensal *E*. *coli* strains. In this study the complete genomes for 13 AIEC and 11NIEC, all with prior *in-vitro* phenotypic analysis were compared.

Multiple studies have demonstrated that CD patients, particularly those with ileal disease, have altered intestinal microbial biodiversity and composition. Because most of these studies are based on 16S rRNA sequence analysis, they do not address alterations in microbial function, or in subgroups within identified species. Shotgun bacterial DNA metagenomics and bacterial metatranscriptomics measure alterations in microbial function more directly than does 16S rRNA sequence analysis. The advantage of bacterial transcriptomic data over shotgun metagenomics data is that the former provides information on which bacterial genes are actually transcribed. In this study we compared the transcriptomes of a reference AIEC strain, LF82 to a control strain HS to identify genes associated with the AIEC phenotype. We selected HS as the control strain which was previously demonstrated to be non-invasive \[[@pone.0130902.ref028]\].

A comparative analysis of genes shared between the LF82 and HS genomes indicated that many of the DEG had a relatively low fold change (\~ 2--4 fold) making them less suited for clinical assays. Up-regulated genes in LF82 are involved in many key pathways including iron metabolism, supporting the recent report that AIEC strains are enriched for genes involved in iron utilization \[[@pone.0130902.ref037]\], a feature of many B2 phylotype members. Comparison of the transcriptional profiles revealed a significant effect of growth conditions (see [Fig 1](#pone.0130902.g001){ref-type="fig"}). We identified six genes with no detectable expression in HS ([Table 2](#pone.0130902.t002){ref-type="table"}) at both growth conditions. Four of the genes code for identical proteins in the enteropathogenic bacteria *Salmonella* and *Shigella*. Further characterization of these proteins in AIEC and non-invasive *E*. *coli* strains is necessary to determine if they are a component of the AIEC phenotype.

In the comparative analysis of RNA-seq data, 747 CDS that mapped to the LF82 genome did not share homology with CDS in HS ([S1 Table](#pone.0130902.s005){ref-type="supplementary-material"}). We extended our comparative analysis to 13 *E*. *coli* strains with the AIEC pathotype and 11 NIEC ([Table 1](#pone.0130902.t001){ref-type="table"}). Using a subtractive genomics approach, we found that the 166 CDS present only in LF82 were not homologous in all 11 NIEC ([S1 Table](#pone.0130902.s005){ref-type="supplementary-material"}). However, none of the 166 CDS were present in the 13 AIEC strains surveyed. This observation supports the concept that the AIEC pathovar is formed by a heterogeneous collection of serogroups and serotypes. As shown in [Table 3](#pone.0130902.t003){ref-type="table"}, AIEC genomes are enriched in genes belonging to the *pdu* operon, the *ibe* operon, and the type VI secretion system \[[@pone.0130902.ref034], [@pone.0130902.ref037], [@pone.0130902.ref038]\]. The *pdu* operon is a component of a metabolic pathway required for fucose utilization \[[@pone.0130902.ref063]\], and is present in enterpathogenic bacteria and offers a competitive advantage for energy production under anaerobic conditions \[[@pone.0130902.ref034], [@pone.0130902.ref063]\]. The *ibeA* gene (invasion of brain endothelium) encodes an invasion protein found in several extraintestinal pathogenic *E*. *coli* (ExPEC) strains\[[@pone.0130902.ref064]\]. This gene may also play a role in *E*. *coli* resistance to H~2~O~s~ stress \[[@pone.0130902.ref065]\]. *IbeA* is a necessary component for invasion of IECs and absence or mutation of this gene limits survival of AIEC within macrophage\[[@pone.0130902.ref066]\]. The type VI secretion system has been implicated in targeting other bacterial and eukaryotic cells \[[@pone.0130902.ref067]\]. We found homologous CDS for *chuA* and *yersiniabactin*, in 6 of 11 NIEC. These iron uptake genes are enriched among AIEC strains \[[@pone.0130902.ref037]\] and other pathogenic E. coli including ExPEC and EHEC. However, it remains to be determined whether these genes are expressed in the noninvasive strains. This analysis is limited by the fact that growth in pure cultures represents a very different environment than within the human intestine, and thus does not take into consideration complex microbe-microbe and host-microbe interactions. In addition, our subtractive genomics approach was limited to CDS expressed in the reference AIEC strain LF82. NRG857C has a genome that is highly similar to LF82 however, CDS in NRG857C but absent in LF82 were present in as many as six of the 13 other AIEC strains. Additional CDS that were homologous among three or more AIEC except LF82 and absent in the 11 NIEC are listed in [S3 Table](#pone.0130902.s007){ref-type="supplementary-material"}. Nonetheless, the results of this analysis provide a useful baseline repertoire of *E*. *coli* transcriptional patterns that may aid in the analysis of complex patient based metatranscriptomic data.

Among the 166 CDS mapping to the LF82 genome, we identified four potential signature transcripts belonging to CRISPR-associated (Cas) genes. These genes map to a region of the LF82 genome that is highly specific \[[@pone.0130902.ref037]\] and in our analysis these CDS were conserved in 4 of 6 AIEC strains. We did not find homologous CDS in DEC, although they are homologous to CDS in three ExPEC. Among the strains with these specific Cas genes, four of the AIEC strains and the three ExPEC are of the B2 phylotype. AIEC of the B2 phylotype are described to be among the most abundant and the most virulent \[[@pone.0130902.ref068]\]. CRISPR-Cas forms the adaptive immunity system \[[@pone.0130902.ref069]--[@pone.0130902.ref071]\]. Bacterial strains express Cas proteins that recognize foreign genetic elements in plasmids and phages and insert fragments of the exogenous DNA into their own genomes. Most *E*. *coli* harbor CRISPR-Cas systems that belong to subtype I-E \[[@pone.0130902.ref072]\]. LF82 has the I-F system which has 3 CRISPR arrays and an operon of 6 cas-F genes (*cas6f*, *csy3*, *csy2*, *csy1*, *cas2*, *cas3*, and *cas1*) \[[@pone.0130902.ref072]\]. This system is also found in *Yersinia pestis* an enterotoxigenic *E*. *coli* (strain B7A) and a subset of B2 phylotype *E*. *coli* \[[@pone.0130902.ref072]\]. Toro et al, \[[@pone.0130902.ref073]\] examined the relationship between CRISPR-Cas systems and virulence in Shiga toxin-producing *E*. *coli* (STEC) and observed conservation of CRIPR spacer contents among strains of the same serotype and that the highly virulent STEC strains had fewer spacers within CRISPR arrays. Two other groups have recently identified CRISPR-Cas gene loci for the development of serotype-specific PCR assays of STEC \[[@pone.0130902.ref074], [@pone.0130902.ref075]\] and *Salmonella enterica* serotypes Typhi and Paratyphi A \[[@pone.0130902.ref076]\].

We analyzed 53 fecal samples ([Table 6](#pone.0130902.t006){ref-type="table"}) using 4 Cas gene assays and 35.7% of CD compared to 6.2% of non-IBD control samples (p = 0.02) revealed positive assays for 3 of the 4 assays. Using the *pduC* primers described in Dogan et al\[[@pone.0130902.ref034]\], expression of the *pduC* gene was detected in 21.4% CD compared to 25% of non-IBD controls (p = 1.0). For the excisionase gene 64% of CD compared to 44% of non-IBD control samples (p = 0.34) had positive assays. We also analyzed 38 parallel ileal biopsy samples ([Table 7](#pone.0130902.t007){ref-type="table"}) and 50% of CD compared to 13% of non-IBD control samples (p = 0.04) had positive assays. Expression of the *pduC* gene was detected in 17% CD compared to 4% of non-IBD controls (p = 0.27). For the excisionase gene 33% of CD compared to 0% of non-IBD control samples (p = 0.0095) had positive assays. All 4 excisionase positive samples were correspondingly positive for Cas genes. The p-values for the Cas assays did not reach significance after applying the Bonferroni correction for multiple comparisons (p \<0.01). Nevertheless we observed a similar trend in fecal and/or ileal biopsies for all four of the Cas genes tested. Our data suggests the Cas genes may serve as promising AIEC biomarkers; this will need to be confirmed in a larger set of patient samples. We did not detect a significant difference in *E*. *coli* 16S rRNA gene expression (ΔCT) relative to total bacteria in cases compared to non-IBD controls.

Altogether our sample sizes were small and *pduC* expression was less discriminating for AIEC infected samples. However, it may be a useful target for therapeutic intervention as previously described. It is also possible that other *pdu* operon genes are more specific and could serve as better targets. Our study is consistent with other reports that no single gene is able to distinguish AIEC from NIEC. Furthermore, it remains to be demonstrated whether any candidate AIEC signature transcripts with utility as a microbial biomarker, has a functional role in pathogenicity.

In summary, these results identify potential candidate AIEC signature transcripts, which may be more prevalent among CD patients than non-IBD patients and serve as proof of principle for our comparative genomic/transcriptomic analysis of AIEC and NIEC.

Supporting Information {#sec019}
======================

###### Specific CAS genes are detected in AIEC by PCR.

Agarose gel electrophoresis analysis of PCR products obtained from reactions using forward and reverse primers of the Cas genes LF82_091 and LF82_092, with E. coli 16S rRNA as a positive control. Positions of molecular size standards (in bp) are indicated, also see [methods](#sec002){ref-type="sec"}.

(TIF)

###### 

Click here for additional data file.

###### Specific CAS genes are detected in AIEC by PCR.

Agarose gel electrophoresis analysis of PCR products obtained from reactions using forward and reverse primers of the Cas genes LF82_088 and LF82_093, with E. coli 16S as a positive control. Positions of molecular size standards (in bp) are indicated, also see [methods](#sec002){ref-type="sec"}.

(TIF)

###### 

Click here for additional data file.

###### Up-regulated and Down regulated transcripts in LF82 and HS.

**Table A. Up-regulated transcripts in LF82 compared to HS.** RNA was extracted from bacteria at exponential (2h) and stationary (24h) phases of growth in pure cultures and RNA sequencing completed. Expression level of homologous CDS in LF82 and HS is compared at 2 h, 24h and at both time points using edgeR. Up-regulated CDS with fold change ≥ 2, FDR \<0.05. The RPKM values for LF82 and HS are shown. **Table B. Down-regulated transcripts in LF82 compared to HS cultures.** RNA was extracted from bacteria at exponential (2h) and stationary (24h) phases of growth in pure cultures and RNA sequencing completed. Expression level of homologous CDS in LF82 and HS is compared at 2 h, 24h and at both time points using edgeR. Up-regulated CDS with fold change ≥ 2, FDR \<0.05. The RPKM values for LF82 and HS are shown.

(XLSX)

###### 

Click here for additional data file.

###### GO functional categories in LF82 and HS.

Table A. Up-regulated GO-categories (FDR \<0.05) in LF82 compared to HS cultures at 2h. Table B. Up-regulated GO-categories (FDR \< 0.05) in LF82 compared to HS cultures at 24h. Table C. Down-regulated GO categories (FDR \<0.05) in LF82 compared to HS cultures at 2h. Table D. Down-regulated GO categories (FDR \<0.05) in LF82 compared to HS cultures at 2h.

(XLSX)

###### 

Click here for additional data file.

###### LF82 transcripts that lack homology (\< 85% sequence identity) within 11 non-invasive *E*. *coli* strains.

(XLSX)

###### 

Click here for additional data file.

###### Forward and reverse primers for RT-qPCR assays.

(DOCX)

###### 

Click here for additional data file.

###### AIEC genes that do not share sequence homology (\<85% sequence identity) with LF82 or non-invasive *E*. *coli* strains.

(XLSX)

###### 

Click here for additional data file.
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